Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study
Mark Rosenthal(The Royal Melbourne Hospital), Warren Mason(Princess Margaret Cancer Centre), John DeGroot(University of California, San Francisco), Patrick Y. Wen(Dana-Farber Cancer Institute), V Donnet(Novartis (France)), Miguel Gil‐Gil(GEICAM – Spanish Breast Cancer Group), Mona El-Hashimy(Novartis (United States)), Mario Campone(Institut de Cancérologie de l'Ouest), Olivier Chinot(Aix-Marseille Université), Ahmed Idbaïh(Centre National de la Recherche Scientifique), Jeffrey Raizer(Northwestern University), David Mills(Novartis (Switzerland)), Paul M. Clément(Universitair Ziekenhuis Leuven), Estela Pineda(Hospital Clínic de Barcelona), Hui Gan(Austin Hospital)
Cited by 35
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Paraneoplastic anti– <i>N</i> ‐methyl‐ <scp>D</scp> ‐aspartate receptor encephalitis associated with ovarian teratoma
|Annals of Neurology|2007|2.5k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k